- Home
- ULBI vs AGEN Comparison
ULBI vs AGEN Comparison
Compare ULBI & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULBI
- AGEN
- Stock Information
- Founded
- ULBI 1990
- AGEN 1994
- Country
- ULBI United States
- AGEN United States
- Employees
- ULBI N/A
- AGEN N/A
- Industry
- ULBI Industrial Machinery/Components
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ULBI Miscellaneous
- AGEN Health Care
- Exchange
- ULBI Nasdaq
- AGEN Nasdaq
- Market Cap
- ULBI 112.3M
- AGEN 126.8M
- IPO Year
- ULBI 1992
- AGEN 2000
- Fundamental
- Price
- ULBI $5.64
- AGEN $4.37
- Analyst Decision
- ULBI Strong Buy
- AGEN Buy
- Analyst Count
- ULBI 1
- AGEN 2
- Target Price
- ULBI $14.00
- AGEN $14.50
- AVG Volume (30 Days)
- ULBI 43.0K
- AGEN 518.3K
- Earning Date
- ULBI 11-18-2025
- AGEN 11-10-2025
- Dividend Yield
- ULBI N/A
- AGEN N/A
- EPS Growth
- ULBI N/A
- AGEN N/A
- EPS
- ULBI 0.19
- AGEN N/A
- Revenue
- ULBI $178,853,000.00
- AGEN $106,829,000.00
- Revenue This Year
- ULBI $31.30
- AGEN $60.49
- Revenue Next Year
- ULBI $6.24
- AGEN N/A
- P/E Ratio
- ULBI $28.93
- AGEN N/A
- Revenue Growth
- ULBI 5.86
- AGEN N/A
- 52 Week Low
- ULBI $4.07
- AGEN $1.38
- 52 Week High
- ULBI $9.52
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- ULBI 29.57
- AGEN 55.93
- Support Level
- ULBI $5.65
- AGEN $3.63
- Resistance Level
- ULBI $7.13
- AGEN $4.67
- Average True Range (ATR)
- ULBI 0.31
- AGEN 0.26
- MACD
- ULBI -0.14
- AGEN 0.07
- Stochastic Oscillator
- ULBI 0.00
- AGEN 66.04
About ULBI Ultralife Corporation
Ultralife Corp provides products and services ranging from power solutions to communications and electronics systems to customers across the globe in the government and defense, medical, safety and security, energy, and industrial sectors. The company designs, manufactures, installs, and maintains power and communications systems including rechargeable and non-rechargeable batteries, charging systems, communications and electronics systems and accessories, and custom-engineered systems. The company's segments include Battery and Energy Products, and Communications Systems. It generates maximum revenue from the Battery and Energy Products segment, and from the U.S. The Battery & Energy Products segment includes Lithium 9-volt, cylindrical, and various other non-rechargeable batteries.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).